StemCell Therapy

The 67 rating InvestorsObserver gives to Blueprint Medicines Corp (BPMC) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 84 percent of stocks in the Biotechnology industry, BPMCs 67 overall rating means the stock scores better than 67 percent of all stocks.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

Blueprint Medicines Corp (BPMC) stock is trading at $99.43 as of 3:25 PM on Wednesday, Oct 7, a gain of $2.88, or 2.98% from the previous closing price of $96.55. The stock has traded between $97.13 and $100.52 so far today. Volume today is 381,700 compared to average volume of 494,247.

Click Here to get the full Stock Score Report on Blueprint Medicines Corp (BPMC) Stock.

View original post here:
Is Blueprint Medicines Corp (BPMC) Stock Near the Top of the Biotechnology Industry? - InvestorsObserver

A rating of 3 puts Aptorum Group Ltd (APM) near the bottom of the Biotechnology industry according to InvestorsObserver. Aptorum Group Ltd's score of 3 means it scores higher than 3% of stocks in the industry. Aptorum Group Ltd also received an overall rating of 8, putting it above 8% of all stocks. Biotechnology is ranked 25 out of the 148 industries.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Aptorum Group Ltd (APM) stock is trading at $2.79 as of 1:12 PM on Wednesday, Oct 7, an increase of $0.10, or 3.72% from the previous closing price of $2.69. The stock has traded between $2.70 and $2.99 so far today. Volume today is 2,313,374 compared to average volume of 2,976,804.

Click Here to get the full Stock Score Report on Aptorum Group Ltd (APM) Stock.

Read the original:
Is Aptorum Group Ltd (APM) Stock Near the Top of the Biotechnology Industry? - InvestorsObserver

A rating of 54 puts Wave Life Sciences Ltd (WVE) near the middle of the Biotechnology industry according to InvestorsObserver. Wave Life Sciences Ltd's score of 54 means it scores higher than 54% of stocks in the industry. Wave Life Sciences Ltd also received an overall rating of 51, putting it above 51% of all stocks. Biotechnology is ranked 22 out of the 148 industries.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

Wave Life Sciences Ltd (WVE) stock is trading at $8.96 as of 11:28 AM on Tuesday, Oct 6, a gain of $0.45, or 5.29% from the previous closing price of $8.51. The stock has traded between $8.66 and $9.14 so far today. Volume today is below average. So far 748,888 shares have traded compared to average volume of 1,771,971 shares.

Click Here to get the full Stock Score Report on Wave Life Sciences Ltd (WVE) Stock.

Read more from the original source:
Where Does Wave Life Sciences Ltd (WVE) Stock Fall in the Biotechnology Field? - InvestorsObserver

The 48 rating InvestorsObserver gives to LogicBio Therapeutics Inc (LOGC) stock puts it near the middle of the Biotechnology industry. In addition to scoring higher than 51 percent of stocks in the Biotechnology industry, LOGCs 48 overall rating means the stock scores better than 48 percent of all stocks.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 48 would rank higher than 48 percent of all stocks.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

LogicBio Therapeutics Inc (LOGC) stock is trading at $7.64 as of 11:48 AM on Wednesday, Oct 7, a gain of $0.81, or 11.86% from the previous closing price of $6.83. The stock has traded between $6.89 and $7.92 so far today. Volume today is low. So far 186,868 shares have traded compared to average volume of 257,546 shares.

Click Here to get the full Stock Score Report on LogicBio Therapeutics Inc (LOGC) Stock.

Go here to read the rest:
Is LogicBio Therapeutics Inc (LOGC) a Winner in the Biotechnology Industry? - InvestorsObserver

Newswise October 6, 2020 Accelerated crop improvement is needed to meet both global population growth and climate change generated stresses on crops. TheCrop Biotechnology, physiology and translational genomics to feed and fuel the worldsymposium at theTranslating Visionary Science to Practice ASA, CSSA, SSSA International Annual Meetingwill address these topics.

The meeting is being held virtually, Nov. 9-13, 2020 and is hosted by the American Society of Agronomy, Crop Science Society of America and Soil Science Society of America. Media are invited; preregistration is required.

The presentations are:

Presentations may be watched asynchronously, and there will be a scheduled Q&A time to speak with presenters during the meeting. Presentations will be available for online viewing for 90 days after the meeting for all registrants. For more information about theTranslating Visionary Science to Practice 2020meeting,visithttps://www.acsmeetings.org/.

Media are invited to attend the conference. Pre-registration by Nov. 2, 2020 is required. Visithttps://www.acsmeetings.org/mediafor registration information.

To speak with one of the scientists, contact Susan V. Fisk, 608-273-8091,sfisk@sciencesocieties.orgto arrange an interview.

Go here to read the rest:
Crop Biotechnology, physiology and translational genomics to feed and fuel the world - Newswise

(September 2020):WMRsLatest Study on Biotechnology Separation Systems Market report 2020-2027 providesan Overview of the current market situation,competitive analysis, product scope, market research, opportunities, driving force, and market risks. The report contains market forecast to 2027 related to market size, Consumption, gross margin, price,revenue, production, CAGR and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market.

The Biotechnology Separation Systems market report provides a basic overview of the industry, including definitions, classifications, applications, and chain structures. Biotechnology Separation Systems market analysis is provided to international markets, including development trends, competitive environment analysis, and key regions development status.

Get the FREE Report Sample (Includes- Keyplayers Profiles, Table and Figures, ToC):https://www.worldwidemarketreports.com/sample/393197

The major manufacturers covered in this report: TERUMO, Wego, Fresenius, Grifols, Haemonetics, Macopharma, JMS, Neomedic, STT, AdvaCare

The Impact Analysis of Coivd-19 on Biotechnology Separation Systems industry:

Our analysts monitoring the situation across the globe explains that the market will generate remunerative prospects for producers post COVID-19 crisis. The report aims to provide an additional illustration of the latest scenario, economic slowdown, and COVID-19 impact on the overall industry.

The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; emergency declared in many countries; massive slowing of the supply chain; stock market unpredictability; falling business assurance, growing panic among the population, and uncertainty about future.

COVID-19 can affect the global Biotechnology Separation Systems economy in 3 main ways: by directly affecting production and demand, by creating supply chain and market disturbance, and by its financial impact on firms and financial markets.

Get the Free Analysis on Coivd-19with Report, here you can ask for the Structured Report:https://www.worldwidemarketreports.com/covidimpact/393197

Table of Content (TOC) of Biotechnology Separation Systems Market 2020:Chapter 1 Introduction and OverviewChapter 2 Industry Cost Structure and Economic ImpactChapter 3 Rising Trends and New Technologies with Major key playersChapter 4 Global Biotechnology Separation Systems Market Analysis, Trends, Growth FactorChapter 5 Biotechnology Separation Systems Market Application and Business with Potential AnalysisChapter 6 Global Biotechnology Separation Systems Market Segment, Type, ApplicationChapter 7 Global Biotechnology Separation Systems Market Analysis (by Application, Type, End-User)Chapter 8 Major Key Vendors Analysis of Biotechnology Separation Systems MarketChapter 9 Development Trend of AnalysisChapter 10 Covid-19 AnalysisChapter 10 Conclusion

Any quiry or Customization in ToC, place hre:https://www.worldwidemarketreports.com/quiry/393197

Benefits of buying Overbed Table Market Report:

Else, Contact Us:

Mr. ShahWorldwide Market ReportsSeattle, WA 98154,U.S.Email: sales@worldwidemarketreports.com

Link:
Biotechnology Separation Systems Market 2020 Industry Development Analysis, Global Trends, Size, Share, Growth Factors, CAGR Status, Industry Insights...

A rating of 84 puts Esperion Therapeutics Inc (ESPR) near the top of the Biotechnology industry according to InvestorsObserver. Esperion Therapeutics Inc's score of 84 means it scores higher than 84% of stocks in the industry. Esperion Therapeutics Inc also received an overall rating of 67, putting it above 67% of all stocks. Biotechnology is ranked 27 out of the 148 industries.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 67 would rank higher than 67 percent of all stocks.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Esperion Therapeutics Inc (ESPR) stock is trading at $35.73 as of 11:45 AM on Monday, Oct 5, a rise of $1.55, or 4.53% from the previous closing price of $34.18. The stock has traded between $34.56 and $36.18 so far today. Volume today is low. So far 105,952 shares have traded compared to average volume of 508,530 shares.

Click Here to get the full Stock Score Report on Esperion Therapeutics Inc (ESPR) Stock.

Continue reading here:
Where Does Esperion Therapeutics Inc (ESPR) Stock Fall in the Biotechnology Field? - InvestorsObserver

Vancouver, British Columbia, Canada - TheNewswire - October 5, 2020 - Global Cannabis Applications Corp. ("GCAC" or the "Company") (CSE:APP) , FSE: 2FA, (OTC:FUAPF), a leading commercial licensor of proprietary Data and AI technologies to the medical cannabis industry, today announced that it has signed a Memorandum of Understanding ("MOU") with Purity-IQ Incorporated of Canada ("Purity-IQ") (http://purity-iq.com/) to integrate the Purity-IQ Cannabis Authenticity and Purity Standard (CAPS) and its Fingerprint(TM) technology with the GCAC efficacy platform; with a focus on the Canadian medical cannabis and adult-use markets, which are forecast to grow to CA$4.1 billion in 20211.

Following on from its TraceLocker announcement on September 3rd, GCAC is attracting key players in the Canadian medical cannabis space. The company's MOU with Purity-IQ is a significant endorsement of the GCAC blockchain compliance and medical efficacy data collection platform. The proposed cooperation integrates GCAC's efficacy-data with Purity-IQ's CAPS Fingerprint(TM) service, a unique genetic and chemical profile of cannabis cultivars.

GCAC's blockchain medical efficacy smartphone app immutably links a specific Purity-IQ CAPS Fingerprint(TM) cultivar directly to a consumer's anonymous efficacy attestations. This is set to revolutionize the traceability of cannabis efficacy and bring it more in line with formal medical-trial information that a traditional dispensing pharmacist would be able to reference.

Purity-IQ can uniquely identify a cultivar based on a metabolite profile using Nuclear Magnetic Resonance (NMR) and DNA chip bioinformatics. The intent is for Purity-IQ Fingerprints to be referenced by GCAC's efficacy platform to verify 'batch-to-batch' consistency in medical cannabis efficacy programs.

GCAC's CEO, Brad Moore "I have no doubt that our smartphone efficacy-data platform is an industry leader for cannabis. Bringing the Purity-IQ scientific fingerprinting of cannabis cultivars, to which our consumers will report their efficacy, really builds a picture of what works for a consumer and what doesn't. This is where medical cannabis needs to get to and, we're bringing it there!"

Brad Moore continued, "With our blockchain truths and efficacy data-sets, medical practitioners, pharmacists, cultivators and processors gain efficacy data previously only found in formal drug trials. We change that and bring the wisdom-of-the-crowd to bear for medical cannabis efficacy."

Under the agreement, GCAC contributions regarding efficacy are the intellectual property ("IP") of GCAC. Securing GCAC's IP creates an inherent difficulty in replicating, or directly competing with, GCAC's medical cannabis solutions, and this is what the company believes makes GCAC one of the most exciting efficacy platforms in the cannabis and RegTech space.

1 https://www.yahoo.com/news/which-pot-stocks-will-survive-cannabis-bankruptcy-risk-131732204.html

About Global Cannabis Applications Corp.

Global Cannabis Applications Corp. is a global leader in designing, developing, marketing and acquiring innovative data technologies for the medical cannabis industry. The Citizen Green platform is the world's first end-to-end - from patient to regulator - medical cannabis data solution. It uses six core technologies: mobile applications, artificial intelligence, regtech, smart databases, blockchain and GCAC smart rewards to qualify candidates for clinical studies. These technologies facilitate the proliferation of digital conversations by like-minded people in the medical cannabis community. Driven by digital and cannabis industry experts, GCAC is focused on viral global expansion by providing the best digital experience in the cannabis market.

For more Company information, please visit http://www.cannappscorp.com, or review its profiles on http://www.sedar.com and on the Canadian Securities Exchange's website (www.thecse.com).

Purity-IQ IncorporatedPurity-IQ is a Canadian biotechnology company based in Mississauga, Ontario. It is committed to innovation in research and development and in the commercialization of practical and affordable validated quality assurance standards and tools, designed to further support brand product claims related to identity, authenticity, and purity. Purity-IQ focuses on commodities and inputs for the food, drug, beverage, natural health products and cannabis industries.

To schedule an interview, please contact: For more information, please contact:

Bradley Moore Corporate Communications

Chief Executive Officer Telephone: +1 (800) 409-5679

Email: bmoore@cannappscorp.com Email: info@cannappscorp.com

Forward-Looking Information

This news release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of GCAC. Forward-looking information is based on certain key expectations and assumptions made by the management of GCAC. Although management of the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because GCAC can give no assurance that they will prove to be correct. Forward-looking statements contained in this news release are made as of the date of this news release. GCAC disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy and accuracy of this information.

See the original post here:
GCAC Strengthens Its Medical Cannabis Efficacy Platform with Purity-IQ Biotechnology to Address a $4.1 Billion Market Opportunity - TheNewswire.ca

The agricultural biotechnologybusiness is anticipated to augment business germination in the projection period of 2020 to 2027 reckoning to USD 74.55 billion by 2027 expanding at an annual growth of 9.94% in the above-mentioned projection years.

The major players covered in the agricultural biotechnology market report areKWS SAAT SE & Co. KGaA, ChemChina, Corteva., Limagrain, MITSUI & CO., LTD., AgPlenus ltd., Biomica, Evogene Ltd., Canonic ltd., Bayer AG, Valent BioSciences LLC, Nufarm Limited, Marrone Bio Innovations., Performance Plants Inc., ADAMA Ltd. among other domestic and global players. Market share data is available for global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Download Sample PDF Copy of Reporthttps://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-agricultural-biotechnology-market

Global Agricultural Biotechnology Market Scope and Market Size

Agricultural biotechnology market is segmented on the basis of type, application, organism type, technology, and product. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

Inquiry For Customize Report With Discount Athttps://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-agricultural-biotechnology-market

Insights of the Study

Global Agricultural Biotechnology Market Drivers & Restraints :

To know more about the studyhttps://www.databridgemarketresearch.com/reports/global-agricultural-biotechnology-market

About Us:

Data Bridge Market Researchset forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. GetCustomizationandDiscounton Report by emailing[emailprotected]. We are content with our glorious 99.9 % client satisfying rate.

Contact:

Data Bridge Market ResearchUS: +1 888 387 2818UK: +44 208 089 1725Hong Kong: +852 8192 7475Email:[emailprotected]

See the rest here:
Covid-19 Update:Agricultural Biotechnology Market 2020||To Witness The Highest Growth Globally In Coming Years || MITSUI & CO., LTD., AgPlenus...

The Coalition of Epidemic Preparedness for Innovation (CEPI), a global initiative to develop vaccines against emerging epidemics, has named Translational Health Science and Technology Institute (THSTI), an autonomous institute of the Department of Biotechnology (DBT), as part of the Global Network of Laboratories for centralized assessment of Covid-19 vaccine candidates that are under development.

The Faridabad-based laboratory, under DBT, is one of the six laboratories that have been recognised by the CEPI. The CEPI network will initially involve six labs - one each in Canada, Britain, Italy, the Netherlands, Bangladesh and India, for the assessment of Covid-19 vaccine development.

Under the CEPI Global network, all the laboratories will use the same reagents and follow a common set of protocols to measure the immune response of multiple vaccine candidates under development and trial.

The Department of Biotechnology, Government of India, is supporting efforts for Covid-19 vaccine development and testing. THSTI runs comparability studies with other laboratories internationally and will form an important part of the global network, said DBT Secretary Renu Swarup.

We are very pleased that the bioassay laboratory at Translational Health Science and Technology Institute, an autonomous institute of Department of Biotechnology, has been identified by CEPI for centralised immunoassay analysis for COVID 19 vaccines under development globally. It is well-positioned to run comparability studies with other laboratories internationally and will form an important part of the global network. This is another excellent example of Ind CEPI and CEPI partnership, Swarup added.

Read the original:
Department of Biotechnology lab to be part of global Covid-19 vaccine assessment project - ETHealthworld.com

Food Biotechnology Market research Report is an inestimable supply of perceptive information for business strategists. This Food Biotechnology Market study provides comprehensive data which enlarge the understanding, scope and application of this report.

A specific study of competitive landscape of the global Food Biotechnology Market has granted, providing insights into the corporate profiles, financial standing, recent developments, mergers and acquisitions, and therefore the SWOT analysis. This analysis report will provides a transparent program to readers concern regarding the overall market situation to further choose on this market projects.

The Food Biotechnology Market report profiles the successive companies, which includes: ABS Global, Arcadia Biosciences, AquaBounty Technologies, BASF Plant Science, Bayer CropScience AG, Camson Bio Technologies

Get Sample Copy of this Report @ https://www.reportsintellect.com/sample-request/1314522

This report studies the global Food Biotechnology Market status and forecast, categorizes the global Food Biotechnology Market size (value & volume), revenue (Million USD), product price by manufacturers, type, application, and region. Food Biotechnology Market Report by Material, Application and Geography with Global Forecast to 2025 is an connoisseur and extensive research provide details associated with worlds major provincial economic situations, Concentrating on the principle districts (North America, South America Europe, and Asia-Pacific) and the crucial nations (US, Germany, UK, Japan, South Korea, and China).

Reports Intellect analysts are currently working analyzing and integrating their insights on the effect of COVID-19 across diverse industry verticals. These insights are quite promising for different businesses and industries to cope up with this unprecedented downturn and take effective strategic decisions to thrive and proliferate within competitive business ecosystem.

By Types: Transgenic CropsSynthetic Biology Derived Products

By Applications:AnimalsPlants

Market Segment by Regions, regional analysis coversNorth AmericaEuropeAsia-PacificSouth AmericaMiddle East and Africa

Table of Contents

Global Food Biotechnology Market Size, Status and Forecast 20251 Market Overview2 Manufacturers Profiles3 Global Food Biotechnology Sales, Revenue, Market Share andCompetitionby Manufacturer4 Global Food Biotechnology Market Analysis by Various Regions5 North America Food Biotechnology by Countries6 Europe Food Biotechnology by Countries7 Asia-Pacific Food Biotechnology by Countries8 South America Food Biotechnology by Countries9 Middle East and Africas Food Biotechnology by Countries10 Global Food Biotechnology Market Segment by Types11 Global Food Biotechnology Market Segment by Applications12 Food Biotechnology Market Forecast13 Sales Channel, Distributors, Traders and Dealers14 Research Findings and Conclusion15 Appendix

Get a Good Amount of Discount on this report @ https://www.reportsintellect.com/discount-request/1314522

Overview of the chapters analysing the global Food Biotechnology Market in detail:

Reasons why you should buy this report

About Us:-Reports Intellect is your one-stop solution for everythingrelating market researchand market intelligence.

Our team works hard to fetchthe best authentic research reports backed with impeccable data figures that guarantee outstanding resultsanytimefor you.

So, whetheritsthe most recentreport from the researchers or a custom requirement, our team is hereto helpyou within absolute bestmanner.

Contact Us:

[emailprotected]PH + 1-706-996-2486US Address:225 Peachtree Street NE,Suite 400,Atlanta, GA 30303

Read more here:
Food Biotechnology Market Laminar Growth to be witnessed by 2025 & Analysis by ABS Global, Arcadia Biosciences, AquaBounty Technologies, BASF...

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that efficacy results of neratinib in HER2-positive, hormone receptor-positive (HR+), early stage breast cancer (eBC) from the Phase III ExteNET trial were published in Clinical Breast Cancer. The manuscript appears in the October 5, 2020 online issue accessible at https://www.clinical-breast-cancer.com/article/S1526-8209(20)30258-5/fulltext.

ExteNET was a multicenter, randomized, double-blind, Phase III trial of 2,840 HER2-positive eBC patients who received neratinib after neoadjuvant and/or adjuvant therapy with chemotherapy and trastuzumab. Patients were stratified by hormone receptor status and randomly assigned to one year of treatment with either oral neratinib 240 mg/day or placebo. The primary endpoint of the trial was invasive disease-free survival (iDFS) with overall survival as a key secondary endpoint. Within the European Union, neratinib is approved in patients with HR+ breast cancer who initiated treatment within one year of completing an adjuvant trastuzumab containing regimen.

The manuscript presents data focusing on HR+ patients who initiated treatment within a year of completing an adjuvant trastuzumab containing treatment (HR+ /< 1 yr) and subgroups of clinical interest including patients who did not achieve a pathological complete response (no pCR) after neoadjuvant treatment and therefore were at a high risk of disease recurrence. (HR+/ <1 yr, no pCR)

In the HR+ /< 1 yr patient population, the absolute 5-year invasive disease-free survival benefit versus placebo was 5.1% (HR=0.58, 95% CI 0.410.82) and absolute 8-year overall survival benefit was 2.1%. (HR=0.79, 95% CI 0.551.13). The 5-year cumulative incidence of CNS metastases was 0.7% in the neratinib arm and 2.1% in the placebo arm.

In the HR+/ <1 yr, no pCR subgroup of patients that were at a high risk of disease recurrence the absolute 5-year iDFS benefit in the neratinib arm versus placebo was 7.4% (HR=0.60; 95% CI 0.331.07) and the 8-year overall survival benefit was 9.1% (HR=0.47; 95% CI 0.230.92).

Most common grade 3 adverse events were diarrhea (39% vs placebo, 1%; without mandatory anti-diarrheal prophylaxis), vomiting (4% vs <1%), and fatigue (2% vs <1%).

Professor Arlene Chan, Vice Chair Breast Cancer Research Centre WA, said, Deciding on which patients benefit most from a given therapy is an important goal for clinicians. This newly published study provides consistent and durable benefits of neratinib in a subset of HER2-positive early stage breast cancer patients who are considered to be at greater risk of relapse: namely patients with HR+ tumors that did not achieve a pCR after neoadjuvant treatment (no pCR). The benefits demonstrated are meaningful in all endpoints evaluated, including iDFS, OS and CNS recurrence, and thus should help guide future clinical decisions.

Hope S. Rugo, MD, Professor of Medicine, University of California San Francisco Comprehensive Cancer Center, said, HER2-positive HR+ patients who do not achieve a pCR are at increased risk of recurrence, even after receiving current standard of care treatment. In a descriptive subset analysis, extended adjuvant therapy with neratinib demonstrated a positive benefit in these patients not only in iDFS, but also in OS. In addition, the trend toward lower CNS involvement is a very important consideration, given the profound impact of CNS metastasis on future prognosis. These data coupled with the recently published data from the CONTROL study, which shows improved tolerability with dose escalation, should allow more patients to benefit from this important therapy.

Alan H. Auerbach, Chief Executive Officer and President of Puma, added, Although there have been many new treatment options for patients with early stage HER2-positive breast cancer, the risk of disease recurrence remains significant and more must be done. These newly published data demonstrate that neratinib provides a clinically meaningful reduction in the risk of recurrence and provides a very important option for these high risk patients.

About HER2-Positive Breast Cancer

Up to 20% of patients with breast cancer tumors over-express the HER2 protein (HER2-positive disease) and in the ExteNET study, 57% of patients were found to have tumors that were hormone-receptor positive. HER2-positive breast cancer is often more aggressive than other types of breast cancer, increasing the risk of disease progression and death. Although research has shown that trastuzumab can reduce the risk of early stage HER2-positive breast cancer recurring, up to 25% of patients treated with trastuzumab experience recurrence within 10 years, the majority of which are metastatic recurrences.

About Puma Biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX is a registered trademark of Puma Biotechnology, Inc.

Further information about Puma Biotechnology may be found at http://www.pumabiotechnology.com.

IMPORTANT SAFETY INFORMATION

NERLYNX (neratinib) tablets, for oral use

INDICATIONS AND USAGE: NERLYNX is a kinase inhibitor indicated:

CONTRAINDICATIONS: None

WARNINGS AND PRECAUTIONS:

ADVERSE REACTIONS:

The most common adverse reactions (reported in 5% of patients) were as follows:

To report SUSPECTED ADVERSE REACTIONS, contact Puma Biotechnology, Inc. at 1-844-NERLYNX (1-844-637-5969) and http://www.NERLYNX.com or FDA at 1-800-FDA-1088 or http://www.fda.gov/medwatch.

DRUG INTERACTIONS:

USE IN SPECIFIC POPULATIONS:

Please see Full Prescribing Information for additional safety information.

To help ensure patients have access to NERLYNX, Puma has implemented the Puma Patient Lynx support program to assist patients and healthcare providers with reimbursement support and referrals to resources that can help with financial assistance. More information on the Puma Patient Lynx program can be found at http://www.NERLYNX.com or 1-855-816-5421.

See the original post:
Puma Biotechnology Announces Publication of Overall Survival Results from Phase III ExteNET Trial Evaluating Neratinib in HER2-Positive, Hormone...

Kaleido Biosciences Inc (KLDO) is around the top of the Biotechnology industry according to InvestorsObserver. KLDO received an overall rating of 62, which means that it scores higher than 62 percent of all stocks. Kaleido Biosciences Inc also achieved a score of 76 in the Biotechnology industry, putting it above 76 percent of Biotechnology stocks. Biotechnology is ranked 34 out of the 148 industries.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Kaleido Biosciences Inc (KLDO) stock is lower by -2.62% while the S&P 500 is up 0.6% as of 1:15 PM on Thursday, Oct 1. KLDO is down -$0.29 from the previous closing price of $11.07 on volume of 311,178 shares. Over the past year the S&P 500 has risen 17.16% while KLDO is up 49.72%. KLDO lost -$2.62 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Kaleido Biosciences Inc (KLDO) Stock.

The rest is here:
Is Kaleido Biosciences Inc (KLDO) Stock Near the Top of the Biotechnology Industry? - InvestorsObserver

The latest report titled Global Nanoparticles in Biotechnology and Pharmaceuticals Market Size, Status and Forecast 2020-2026 aims to enhance your decision-making ability in the business by providing knowledgeable insights related to the market and competitive landscape. The report recognizes vital facts, events, and possible variations in the global Nanoparticles in Biotechnology and Pharmaceuticals market. The report depicts valuable insights related to significant market trends driving the industry. It highlights key opportunities and challenges faced by market leaders while assessing their competitive setting and corporate strategies for the estimated timeline. The report also reveals drivers, trends, the market scope, profitability, demand status, uncertainties, and development forecast from 2020 to 2026 time-period.

The report covers SWOT analysis, market valuation, competitive spectrum, regional share, and revenue predictions. The research studies the global Nanoparticles in Biotechnology and Pharmaceuticals market competition, leading companies, industry environment, emerging opportunities, trends, and crucial segments in the market. Then the study encompasses company profiles, size, production value, product specifications, capacity, and 2020-2026 market shares occupied by each company. The global market size & trends are classified based on the types of products, application segments, and end-user. Each segment expansion is assessed together with the estimation of their growth in the upcoming period.

DOWNLOAD FREE SAMPLE REPORT: https://www.magnifierresearch.com/report-detail/23602/request-sample

NOTE: Our report highlights the major issues and hazards that companies might come across due to the unprecedented outbreak of COVID-19.

Key Segments Studied In The Report:

For competitor segment, the report includes global key players of the market as well as some small players: Roche, GE Healthcare, Merck, Novartis, AMAG Pharmaceuticals, Amgen, Bausch & Lomb, Biogen, Celgene, Gilead, Ipsen, Leadiant Biosciences, nanoComposix, Pacira Pharmaceuticals, Pfizer, Shire,

Segment by product type, this report focuses on consumption, market share, and growth rate of the market in each product type and can be divided into:

Segment by application, this report focuses on consumption, market share, and growth rate of the market in each application and can be divided into: Biotechnology, Pharmaceutical,

The important geographical segments of the global Nanoparticles in Biotechnology and Pharmaceuticals market are as follows: North America (United States, Canada, Mexico), Asia-Pacific (China, Japan, South Korea, India, Australia, Indonesia, Thailand, Malaysia, Philippines, Vietnam), Europe (Germany, France, UK, Italy, Russia, Rest of Europe), Central & South America (Brazil, Rest of South America), Middle East & Africa (GCC Countries, Turkey, Egypt, South Africa, Rest of Middle East & Africa).

Production and consumption Analysis of The Global Nanoparticles in Biotechnology and Pharmaceuticals Market:

One part is about its production and the other part is about its consumption. On the basis of its production, the report analyzes the production, revenue, gross margin of its main manufacturers, and the unit price that they offer in different regions from 2015 to 2019. In terms of consumption, we analyze the consumption volume, consumption value, sale price, import, and export in different regions from 2015 to 2019. We also make a prediction of its production and consumption in the coming 2020-2026.

ACCESS FULL REPORT: https://www.magnifierresearch.com/report/global-nanoparticles-in-biotechnology-and-pharmaceuticals-market-size-23602.html

Key Report Pointers & Highlights:

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

About Us

Magnifier Research is a leading market intelligence company that sells reports of top publishers in the technology industry. Our extensive research reports cover detailed market assessments that include major technological improvements in the industry. Magnifier Research also specializes in analyzing hi-tech systems and current processing systems in its expertise. We have a team of experts that compile precise research reports and actively advise top companies to improve their existing processes. Our experts have extensive experience in the topics that they cover. Magnifier Research provides you the full spectrum of services related to market research, and corroborate with the clients to increase the revenue stream, and address process gaps.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: [emailprotected]Web: http://www.magnifierresearch.com

See the original post:
Global Nanoparticles in Biotechnology and Pharmaceuticals Market 2020 Analysis, Types, Applications, Forecast and COVID-19 Impact Analysis 2026 - The...

Abeona Therapeutics Inc (ABEO) is around the bottom of the Biotechnology industry according to InvestorsObserver. ABEO received an overall rating of 34, which means that it scores higher than 34 percent of all stocks. Abeona Therapeutics Inc also achieved a score of 23 in the Biotechnology industry, putting it above 23 percent of Biotechnology stocks. Biotechnology is ranked 27 out of the 148 industries.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 34 means the stock is more attractive than 34 percent of stocks.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

Abeona Therapeutics Inc (ABEO) stock has fallen -5.46% while the S&P 500 is up 1.25% as of 2:03 PM on Wednesday, Sep 30. ABEO is down -$0.06 from the previous closing price of $1.11 on volume of 4,933,979 shares. Over the past year the S&P 500 is higher by 14.86% while ABEO is down -53.95%. ABEO lost -$1.31 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Abeona Therapeutics Inc (ABEO) Stock.

More:
Is Abeona Therapeutics Inc (ABEO) Stock Near the Top of the Biotechnology Industry? - InvestorsObserver

FLORHAM PARK, N.J., Sept. 28, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (PDS Biotech or the Company) (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Companys proprietary Versamune T-cell activating technology, today announced that its Chief Medical Officer, Lauren V. Wood, M.D. will present key data from the companys previously reported Phase 1 trial of PDS0101 and planned Phase 2 clinical studies in patients with advanced HPV-associated malignancies at the World Vaccine Congress, being held virtually September 28 October 1, 2020.

About PDS Biotechnology

PDS Biotech is a clinical-stage immunotherapy company with a growing pipeline of cancer immunotherapies and infectious disease vaccines based on the Companys proprietary Versamune T-cell activating technology platform. Versamune effectively delivers disease-specific antigens for in vivo uptake and processing, while also activating the critical type 1 interferon immunological pathway, resulting in production of potent disease-specific killer T-cells as well as neutralizing antibodies. PDS Biotech has engineered multiple therapies, based on combinations of Versamune and disease-specific antigens, designed to train the immune system to better recognize disease cells and effectively attack and destroy them.

Forward Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 on our current expectations and projections about future events. In some cases, forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions. These statements are based upon current beliefs, expectations, and assumptions and include statements regarding the proposed public offering and anticipated closing. These statements are subject to a number of risks and uncertainties, many of which are difficult to predict, including market conditions, whether the proposed offering is completed, the satisfaction of customary closing conditions related to the proposed offering and the other factors described in PDS Biotechs filings with the SEC. The information in this release is provided only as of the date of this release, and PDS Biotech undertakes no obligation to update any forward-looking statements contained in this release based on new information, future events, or otherwise, except as required by law.

Media & Investor Relations Contact:

Deanne RandolphPDS BiotechnologyPhone: +1 (908) 517-3613Email: drandolph@pdsbiotech.com

James SaliernoThe Ruth GroupPhone: +1 (646) 536-7028 / +1 (973) 255-8361Email: jsalierno@theruthgroup.com

The rest is here:
PDS Biotechnology to Present Results from its Phase 1 Trial of PDS0101 and the Phase 2 Clinical Strategy in Patients with Advanced HPV-Associated...

The 65 rating InvestorsObserver gives to Seelos Therapeutics Inc (SEEL) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 81 percent of stocks in the Biotechnology industry, SEELs 65 overall rating means the stock scores better than 65 percent of all stocks.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

Seelos Therapeutics Inc (SEEL) stock is lower by -6.62% while the S&P 500 has risen 1.25% as of 1:21 PM on Wednesday, Sep 30. SEEL is lower by -$0.07 from the previous closing price of $1.04 on volume of 6,319,446 shares. Over the past year the S&P 500 has gained 14.86% while SEEL has risen 7.78%. SEEL lost -$0.75 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Seelos Therapeutics Inc (SEEL) Stock.

View post:
Is Seelos Therapeutics Inc (SEEL) a Winner in the Biotechnology Industry? - InvestorsObserver

Reports from Quince Market Insights adds to its database of reports of Global Microbioreactor System Market Share, Growth, Trends, and Expected Market Research Study. This report provides a strategic overview of the Global Microbioreactor System Market and the forecasted growth estimates for the future. The main purpose of this report is to help the consumer understand the market as a whole, its meanings and segmentation, market potential, influential trends, and the barriers that it is facing. The Global Microbioreactor System Market report points out national and global business prospects and competitive conditions for Microbioreactor System .

Sample Copy of This Report: https://www.quincemarketinsights.com/request-sample-66040?utm_source=Arshad/dc

Companies Covered: Sartorius, Applikon Biotechnology, Eppendorf, Pall Corporation, PARR, M2p-labs, INFORS HT, PBS Biotech, Sysbiotech, HiTec Zang

Market size estimation and forecasts were given based on a detailed research methodology tailored to the conditions of the demand for Global Microbioreactor System . The Global Microbioreactor System Market has been segmented : By Type (24 Parallel Bioreactors, 48 Parallel Bioreactors, Others), By Application (Pharma, Biotech, Food Industry, Scientific Research Institutes, Others). Strict research and review have been a significant part of the preparation of the study. Those who read the report will get a thorough understanding of the industry.

Microbioreactor System Market

Get ToC for the overview of the premium report @ https://www.quincemarketinsights.com/request-toc-66040?utm_source=Arshad/dc

Industry experts have reviewed and validated the data and information taken from reputable sources such as blogs, business annual reports, journals, and other documents. To offer a detailed picture of the facts and data, diagrams, graphs, pie charts, and other representations have been used. This augments the visual appeal of the report and makes it easier to understand. Major regions covered in the study include North America, Europe, Asia Pacific, Middle East & Africa, and South America.

Make an Enquiry for purchasing this Report @ https://www.quincemarketinsights.com/enquiry-before-buying-66040?utm_source=Arshad/dc

ABOUT US:

QMI has the most comprehensive collection of market research products and services available on the web. We deliver reports from virtually all major publications and refresh our list regularly to provide you with immediate online access to the worlds most extensive and up-to-date archive of professional insights into global markets, companies, goods, and patterns.

Contact:

Quince Market Insights

Office No- A109

Pune, Maharashtra 411028

Phone: APAC +91 706 672 4848 / US +1 208 405 2835 / UK +44 1444 39 0986

Email: [emailprotected]

Web: https://www.quincemarketinsights.com

Read more:
Microbioreactor System Market 2020: What Are The New Innovations By Companies- Sartorius, Applikon Biotechnology, Eppendorf, Pall Corporation, PARR,...

Agricultural Biotechnology Market report puts across the idea of high-level analysis of major market segments and identification of opportunities. This information not only aids businesses in taking sound and proficient decisions but also helps decide the advertising, promotion, marketing and sales strategy more gainfully. Moreover, estimation of strategic options, suggestions of winning action plans and support to make critical bottom-line decisions is also provided by experienced and innovative industry experts. It supports in adjusting the production depending on the conditions of demand in the market which evades the wastage of goods. The market data analysed in this Agricultural Biotechnology Market report makes achieve the business goal and objective in predetermined time frame.

Few of the major competitors currently working in the global Agricultural Biotechnology market are:

Syngenta AG, Monsanto, DuPont, Performance Plants Inc., Global Bio-Chem Technology Group, and ADAMA Agricultural Solutions are some of the key players in this industry

Get Free Sample Report @ https://www.adroitmarketresearch.com/contacts/request-sample/113

A large-scale Agricultural Biotechnology Market report is of great importance for better understanding of the market which leads to high business growth. This market report has a chapter on the global market and all its associated companies with their profiles, which gives valuable data related to their outlook in terms of finances, product portfolios, investment plans, and marketing and business strategies. Agricultural Biotechnology Market research report provides important and meaningful market insights for the business by taking into consideration various factors. Thoroughly analysed market segmentation aspect provides a clear idea about the product consumption based on several factors ranging from type, application, deployment model, end user to geographical region.

Global Agricultural Biotechnology market is set to witness a healthy CAGR in the forecast period of 2019-2026. This rise in market value can be attributed to the surging adoption of AI and IoT along with the involvement of Agricultural Biotechnology vendors

Regional Analysis Includes:

*Asia-Pacific (China, Japan, Korea, India, and Southeast Asia)*Europe (Germany, France, UK, Russia, and Italy etc.)*North America (the United States, Mexico, and Canada.)*South America (Brazil, Argentina, Columbia, etc.)*The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)

Table and Figures Covered in This Report:*Agricultural Biotechnology Market Overview, Scope, Status, and Prospect*Agricultural Biotechnology Market Competition by Manufacturers*Agricultural Biotechnology Market Capacity, Production, Revenue (Value) by Region*Agricultural Biotechnology Market Supply (Production), Consumption, Export, Import by Region*Agricultural Biotechnology Market Production, Revenue (Value), Price Trend by Type*Agricultural Biotechnology Market Analysis by Application*Agricultural Biotechnology Market Manufacturing Cost Analysis*Agricultural Biotechnology Market Industry Effect Factors Analysis*Agricultural Biotechnology Market Forecast*Agricultural Biotechnology Market Research Findings and Conclusion

Access Detailed Report at https://www.adroitmarketresearch.com/industry-reports/agricultural-biotechnology-market

What are the Recent Development of the Market?

Agricultural Biotechnology Market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies focus related to Agricultural Biotechnology Market.

Key Questions Answered:

*What is the size and CAGR of the global Agricultural Biotechnology Market?*What are the key driving factors of the most profitable regional market?*Which are the leading segments of the global market?*How will the global market advance in the coming years?*What are the main strategies adopted in the global market?*What is the nature of competition in the global market?*What growth impetus or acceleration market carries during the forecast period?*Which region may hit the highest market share in the coming era?*What trends, challenges, and barriers will impact the development and sizing of the market?

Still Any Query? Feel Free to Contact our Expert at https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/113

About Us :

Adroit Market Research is an India-based business analytics and consulting company incorporated in 2018. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a Markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable Market insights to help create opportunities that increase their revenues. We follow a code- Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Contact Us :

Ryan JohnsonAccount Manager Global3131 McKinney Ave Ste 600, Dallas,TX75204, U.S.A.Phone No.: USA: +1 972-362 -8199/ +91 9665341414

Read more:
Agricultural Biotechnology Market 2020: by Region, Production, Consumption, Revenue, Market Share, Growth Rate Analysis and Forecast Till 2025 - The...

LOS ANGELES, United States:The report is an all-inclusive research study of the global Interferon market taking into account the growth factors, recent trends, developments, opportunities, and competitive landscape. The market analysts and researchers have done extensive analysis of the global Interferon market with the help of research methodologies such as PESTLE and Porters Five Forces analysis. They have provided accurate and reliable market data and useful recommendations with an aim to help the players gain an insight into the overall present and future market scenario. The Interferon report comprises in-depth study of the potential segments including product type, application, and end user and their contribution to the overall market size.

Get PDF Sample Copy of Report: (Including TOC, List of Tables & Figures, Chart) :https://www.qyresearch.com/sample-form/form/1638467/global-interferon-market

In addition, market revenues based on region and country are provided in the Interferon report. The authors of the report have also shed light on the common business tactics adopted by players. The leading players of the global Interferon market and their complete profiles are included in the report. Besides that, investment opportunities, recommendations, and trends that are trending at present in the global Interferon market are mapped by the report. With the help of this report, the key players of the global Interferon market will be able to make sound decisions and plan their strategies accordingly to stay ahead of the curve.

Competitive landscape is a critical aspect every key player needs to be familiar with. The report throws light on the competitive scenario of the global Interferon market to know the competition at both the domestic and global levels. Market experts have also offered the outline of every leading player of the global Interferon market, considering the key aspects such as areas of operation, production, and product portfolio. Additionally, companies in the report are studied based on the key factors such as company size, market share, market growth, revenue, production volume, and profits.

Key Players Mentioned in the Global Interferon Market Research Report: Roche, Anke Biotechnology, Bayer, Merck & Co, Tri-Prime, Kawin, Genzon Pharma, Novartis, Biogen, Merck KGaA, Zydus Cadila, Huaxin Biotechnology, Harbin Pharmaceutical

Global Interferon Market Segmentation by Product: Assay Kit, Analyzer

Global Interferon Market Segmentation by Application: , Hepatitis, Multiple Sclerosis, Others

The Interferon Market report has been segregated based on distinct categories, such as product type, application, end user, and region. Each and every segment is evaluated on the basis of CAGR, share, and growth potential. In the regional analysis, the report highlights the prospective region, which is estimated to generate opportunities in the global Interferon market in the forthcoming years. This segmental analysis will surely turn out to be a useful tool for the readers, stakeholders, and market participants to get a complete picture of the global Interferon market and its potential to grow in the years to come.

Key questions answered in the report:

Request for customization in Report:https://www.qyresearch.com/customize-request/form/1638467/global-interferon-market

Table of Contents:

1 Interferon Market Overview1.1 Interferon Product Overview1.2 Interferon Market Segment by Type1.2.1 Long-lasting Type1.2.2 Ordinary Type1.3 Global Interferon Market Size by Type (2015-2026)1.3.1 Global Interferon Market Size Overview by Type (2015-2026)1.3.2 Global Interferon Historic Market Size Review by Type (2015-2020)

1.3.2.1 Global Interferon Sales Market Share Breakdown by Type (2015-2026)

1.3.2.2 Global Interferon Revenue Market Share Breakdown by Type (2015-2026)

1.3.2.3 Global Interferon Average Selling Price (ASP) by Type (2015-2026)1.3.3 Global Interferon Market Size Forecast by Type (2021-2026)

1.3.3.1 Global Interferon Sales Market Share Breakdown by Application (2021-2026)

1.3.3.2 Global Interferon Revenue Market Share Breakdown by Application (2021-2026)

1.3.3.3 Global Interferon Average Selling Price (ASP) by Application (2021-2026)1.4 Key Regions Market Size Segment by Type (2015-2020)1.4.1 North America Interferon Sales Breakdown by Type (2015-2026)1.4.2 Europe Interferon Sales Breakdown by Type (2015-2026)1.4.3 Asia-Pacific Interferon Sales Breakdown by Type (2015-2026)1.4.4 Latin America Interferon Sales Breakdown by Type (2015-2026)1.4.5 Middle East and Africa Interferon Sales Breakdown by Type (2015-2026)1.5 Coronavirus Disease 2019 (Covid-19): Interferon Industry Impact1.5.1 How the Covid-19 is Affecting the Interferon Industry

1.5.1.1 Interferon Business Impact Assessment Covid-19

1.5.1.2 Supply Chain Challenges

1.5.1.3 COVID-19s Impact On Crude Oil and Refined Products1.5.2 Market Trends and Interferon Potential Opportunities in the COVID-19 Landscape1.5.3 Measures / Proposal against Covid-19

1.5.3.1 Government Measures to Combat Covid-19 Impact

1.5.3.2 Proposal for Interferon Players to Combat Covid-19 Impact 2 Global Interferon Market Competition by Company2.1 Global Top Players by Interferon Sales (2015-2020)2.2 Global Top Players by Interferon Revenue (2015-2020)2.3 Global Top Players Interferon Average Selling Price (ASP) (2015-2020)2.4 Global Top Manufacturers Interferon Manufacturing Base Distribution, Sales Area, Product Type2.5 Interferon Market Competitive Situation and Trends2.5.1 Interferon Market Concentration Rate (2015-2020)2.5.2 Global 5 and 10 Largest Manufacturers by Interferon Sales and Revenue in 20192.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Interferon as of 2019)2.7 Date of Key Manufacturers Enter into Interferon Market2.8 Key Manufacturers Interferon Product Offered2.9 Mergers & Acquisitions, Expansion 3 Global Interferon Status and Outlook by Region (2015-2026)3.1 Global Interferon Market Size and CAGR by Region: 2015 VS 2020 VS 20263.2 Global Interferon Market Size Market Share by Region (2015-2020)3.2.1 Global Interferon Sales Market Share by Region (2015-2020)3.2.2 Global Interferon Revenue Market Share by Region (2015-2020)3.2.3 Global Interferon Sales, Revenue, Price and Gross Margin (2015-2020)3.3 Global Interferon Market Size Market Share by Region (2021-2026)3.3.1 Global Interferon Sales Market Share by Region (2021-2026)3.3.2 Global Interferon Revenue Market Share by Region (2021-2026)3.3.3 Global Interferon Sales, Revenue, Price and Gross Margin (2021-2026)3.4 North America Interferon Market Size YoY Growth (2015-2026)3.4.1 North America Interferon Revenue YoY Growth (2015-2026)3.4.2 North America Interferon Sales YoY Growth (2015-2026)3.5 Asia-Pacific Interferon Market Size YoY Growth (2015-2026)3.5.1 Asia-Pacific Interferon Revenue YoY Growth (2015-2026)3.5.2 Asia-Pacific Interferon Sales YoY Growth (2015-2026)3.6 Europe Interferon Market Size YoY Growth (2015-2026)3.6.1 Europe Interferon Revenue YoY Growth (2015-2026)3.6.2 Europe Interferon Sales YoY Growth (2015-2026)3.7 Latin America Interferon Market Size YoY Growth (2015-2026)3.7.1 Latin America Interferon Revenue YoY Growth (2015-2026)3.7.2 Latin America Interferon Sales YoY Growth (2015-2026)3.8 Middle East and Africa Interferon Market Size YoY Growth (2015-2026)3.8.1 Middle East and Africa Interferon Revenue YoY Growth (2015-2026)3.8.2 Middle East and Africa Interferon Sales YoY Growth (2015-2026) 4 Global Interferon by Application4.1 Interferon Segment by Application4.1.1 Hepatitis4.1.2 Multiple Sclerosis4.1.3 Others4.2 Global Interferon Sales by Application: 2015 VS 2020 VS 20264.3 Global Interferon Historic Sales by Application (2015-2020)4.4 Global Interferon Forecasted Sales by Application (2021-2026)4.5 Key Regions Interferon Market Size by Application4.5.1 North America Interferon by Application4.5.2 Europe Interferon by Application4.5.3 Asia-Pacific Interferon by Application4.5.4 Latin America Interferon by Application4.5.5 Middle East and Africa Interferon by Application 5 North America Interferon Market Size by Country (2015-2026)5.1 North America Market Size Market Share by Country (2015-2020)5.1.1 North America Interferon Sales Market Share by Country (2015-2020)5.1.2 North America Interferon Revenue Market Share by Country (2015-2020)5.2 North America Market Size Market Share by Country (2021-2026)5.2.1 North America Interferon Sales Market Share by Country (2021-2026)5.2.2 North America Interferon Revenue Market Share by Country (2021-2026)5.3 North America Market Size YoY Growth by Country5.3.1 U.S. Interferon Market Size YoY Growth (2015-2026)5.3.2 Canada Interferon Market Size YoY Growth (2015-2026) 6 Europe Interferon Market Size by Country (2015-2026)6.1 Europe Market Size Market Share by Country (2015-2020)6.1.1 Europe Interferon Sales Market Share by Country (2015-2020)6.1.2 Europe Interferon Revenue Market Share by Country (2015-2020)6.2 Europe Market Size Market Share by Country (2021-2026)6.2.1 Europe Interferon Sales Market Share by Country (2021-2026)6.2.2 Europe Interferon Revenue Market Share by Country (2021-2026)6.3 Europe Market Size YoY Growth by Country6.3.1 Germany Interferon Market Size YoY Growth (2015-2026)6.3.2 France Interferon Market Size YoY Growth (2015-2026)6.3.3 U.K. Interferon Market Size YoY Growth (2015-2026)6.3.4 Italy Interferon Market Size YoY Growth (2015-2026)6.3.5 Russia Interferon Market Size YoY Growth (2015-2026) 7 Asia-Pacific Interferon Market Size by Country (2015-2026)7.1 Asia-Pacific Market Size Market Share by Country (2015-2020)7.1.1 Asia-Pacific Interferon Sales Market Share by Country (2015-2020)7.1.2 Asia-Pacific Interferon Revenue Market Share by Country (2015-2020)7.2 Asia-Pacific Market Size Market Share by Country (2021-2026)7.2.1 Asia-Pacific Interferon Sales Market Share by Country (2021-2026)7.2.2 Asia-Pacific Interferon Revenue Market Share by Country (2021-2026)7.3 Asia-Pacific Market Size YoY Growth by Country7.3.1 China Interferon Market Size YoY Growth (2015-2026)7.3.2 Japan Interferon Market Size YoY Growth (2015-2026)7.3.3 South Korea Interferon Market Size YoY Growth (2015-2026)7.3.4 India Interferon Market Size YoY Growth (2015-2026)7.3.5 Australia Interferon Market Size YoY Growth (2015-2026)7.3.6 Taiwan Interferon Market Size YoY Growth (2015-2026)7.3.7 Indonesia Interferon Market Size YoY Growth (2015-2026)7.3.8 Thailand Interferon Market Size YoY Growth (2015-2026)7.3.9 Malaysia Interferon Market Size YoY Growth (2015-2026)7.3.10 Philippines Interferon Market Size YoY Growth (2015-2026)7.3.11 Vietnam Interferon Market Size YoY Growth (2015-2026) 8 Latin America Interferon Market Size by Country (2015-2026)8.1 Latin America Market Size Market Share by Country (2015-2020)8.1.1 Latin America Interferon Sales Market Share by Country (2015-2020)8.1.2 Latin America Interferon Revenue Market Share by Country (2015-2020)8.2 Latin America Market Size Market Share by Country (2021-2026)8.2.1 Latin America Interferon Sales Market Share by Country (2021-2026)8.2.2 Latin America Interferon Revenue Market Share by Country (2021-2026)8.3 Latin America Market Size YoY Growth by Country8.3.1 Mexico Interferon Market Size YoY Growth (2015-2026)8.3.2 Brazil Interferon Market Size YoY Growth (2015-2026)8.3.3 Argentina Interferon Market Size YoY Growth (2015-2026) 9 Middle East and Africa Interferon Market Size by Country (2015-2026)9.1 Middle East and Africa Market Size Market Share by Country (2015-2020)9.1.1 Middle East and Africa Interferon Sales Market Share by Country (2015-2020)9.1.2 Middle East and Africa Interferon Revenue Market Share by Country (2015-2020)9.2 Middle East and Africa Market Size Market Share by Country (2021-2026)9.2.1 Middle East and Africa Interferon Sales Market Share by Country (2021-2026)9.2.2 Middle East and Africa Interferon Revenue Market Share by Country (2021-2026)9.3 Middle East and Africa Market Size YoY Growth by Country9.3.1 Turkey Interferon Market Size YoY Growth (2015-2026)9.3.2 Saudi Arabia Interferon Market Size YoY Growth (2015-2026)9.3.3 UAE Interferon Market Size YoY Growth (2015-2026) 10 Company Profiles and Key Figures in Interferon Business10.1 Roche10.1.1 Roche Corporation Information10.1.2 Roche Description, Business Overview and Total Revenue10.1.3 Roche Interferon Sales, Revenue and Gross Margin (2015-2020)10.1.4 Roche Interferon Products Offered10.1.5 Roche Recent Development10.2 Anke Biotechnology10.2.1 Anke Biotechnology Corporation Information10.2.2 Anke Biotechnology Description, Business Overview and Total Revenue10.2.3 Anke Biotechnology Interferon Sales, Revenue and Gross Margin (2015-2020)10.2.4 Roche Interferon Products Offered10.2.5 Anke Biotechnology Recent Development10.3 Bayer10.3.1 Bayer Corporation Information10.3.2 Bayer Description, Business Overview and Total Revenue10.3.3 Bayer Interferon Sales, Revenue and Gross Margin (2015-2020)10.3.4 Bayer Interferon Products Offered10.3.5 Bayer Recent Development10.4 Merck & Co10.4.1 Merck & Co Corporation Information10.4.2 Merck & Co Description, Business Overview and Total Revenue10.4.3 Merck & Co Interferon Sales, Revenue and Gross Margin (2015-2020)10.4.4 Merck & Co Interferon Products Offered10.4.5 Merck & Co Recent Development10.5 Tri-Prime10.5.1 Tri-Prime Corporation Information10.5.2 Tri-Prime Description, Business Overview and Total Revenue10.5.3 Tri-Prime Interferon Sales, Revenue and Gross Margin (2015-2020)10.5.4 Tri-Prime Interferon Products Offered10.5.5 Tri-Prime Recent Development10.6 Kawin10.6.1 Kawin Corporation Information10.6.2 Kawin Description, Business Overview and Total Revenue10.6.3 Kawin Interferon Sales, Revenue and Gross Margin (2015-2020)10.6.4 Kawin Interferon Products Offered10.6.5 Kawin Recent Development10.7 Genzon Pharma10.7.1 Genzon Pharma Corporation Information10.7.2 Genzon Pharma Description, Business Overview and Total Revenue10.7.3 Genzon Pharma Interferon Sales, Revenue and Gross Margin (2015-2020)10.7.4 Genzon Pharma Interferon Products Offered10.7.5 Genzon Pharma Recent Development10.8 Novartis10.8.1 Novartis Corporation Information10.8.2 Novartis Description, Business Overview and Total Revenue10.8.3 Novartis Interferon Sales, Revenue and Gross Margin (2015-2020)10.8.4 Novartis Interferon Products Offered10.8.5 Novartis Recent Development10.9 Biogen10.9.1 Biogen Corporation Information10.9.2 Biogen Description, Business Overview and Total Revenue10.9.3 Biogen Interferon Sales, Revenue and Gross Margin (2015-2020)10.9.4 Biogen Interferon Products Offered10.9.5 Biogen Recent Development10.10 Merck KGaA10.10.1 Company Basic Information, Manufacturing Base and Competitors10.10.2 Interferon Product Category, Application and Specification10.10.3 Merck KGaA Interferon Sales, Revenue, Price and Gross Margin (2015-2020)10.10.4 Main Business Overview10.10.5 Merck KGaA Recent Development10.11 Zydus Cadila10.11.1 Zydus Cadila Corporation Information10.11.2 Zydus Cadila Description, Business Overview and Total Revenue10.11.3 Zydus Cadila Interferon Sales, Revenue and Gross Margin (2015-2020)10.11.4 Zydus Cadila Interferon Products Offered10.11.5 Zydus Cadila Recent Development10.12 Huaxin Biotechnology10.12.1 Huaxin Biotechnology Corporation Information10.12.2 Huaxin Biotechnology Description, Business Overview and Total Revenue10.12.3 Huaxin Biotechnology Interferon Sales, Revenue and Gross Margin (2015-2020)10.12.4 Huaxin Biotechnology Interferon Products Offered10.12.5 Huaxin Biotechnology Recent Development10.13 Harbin Pharmaceutical10.13.1 Harbin Pharmaceutical Corporation Information10.13.2 Harbin Pharmaceutical Description, Business Overview and Total Revenue10.13.3 Harbin Pharmaceutical Interferon Sales, Revenue and Gross Margin (2015-2020)10.13.4 Harbin Pharmaceutical Interferon Products Offered10.13.5 Harbin Pharmaceutical Recent Development 11 Interferon Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis11.1 Interferon Key Raw Materials11.1.1 Key Raw Materials11.1.2 Key Raw Materials Price11.1.3 Raw Materials Key Suppliers11.2 Manufacturing Cost Structure11.2.1 Raw Materials11.2.2 Labor Cost11.2.3 Manufacturing Expenses11.3 Interferon Industrial Chain Analysis11.4 Market Opportunities, Challenges, Risks and Influences Factors Analysis11.4.1 Market Opportunities and Drivers11.4.2 Market Challenges11.4.3 Market Risks11.4.4 Porters Five Forces Analysis 12 Market Strategy Analysis, Distributors12.1 Sales Channel12.2 Distributors12.3 Downstream Customers 13 Research Findings and Conclusion 14 Appendix14.1 Methodology/Research Approach14.1.1 Research Programs/Design14.1.2 Market Size Estimation14.1.3 Market Breakdown and Data Triangulation14.2 Data Source14.2.1 Secondary Sources14.2.2 Primary Sources14.3 Author Details14.4 Disclaimer

About Us:

QY Research established in 2007, focus on custom research, management consulting, IPO consulting, industry chain research, data base and seminar services. The company owned a large basic data base (such as National Bureau of statistics database, Customs import and export database, Industry Association Database etc), experts resources (included energy automotive chemical medical ICT consumer goods etc.

See original here:
Interferon Market Growth, Projections, Analysis, Trends and Forecast 2026 | ( Roche, Anke Biotechnology, Bayer) - The Daily Chronicle